Sanofi makes another pipeline deal, tapping Adagene for anti...

Sanofi's rash of dealmaking has continued with a $2.5 billion tie-up with Chinese cancer immunotherapy biotech Adagene, focused on developing a new generation of safer antibody-based therap

China’s Adagene raises $69m for cancer immunotherapies